Better acute graft- versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Haematologica. 2017 May;102(5):806-808. doi: 10.3324/haematol.2017.165266.

Authors

Mahasweta Gooptu¹, John Koreth²

Affiliations

¹ Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA jkoreth@partners.org.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acute Disease
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation
Humans
Immunosuppressive Agents
Tacrolimus*
Transplant Recipients
Transplantation, Homologous

Substances

Immunosuppressive Agents
Tacrolimus